Sign up to save your podcasts
Or
Share Epigenetics. Synergy. Survival. 🧬💊📈 in in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Epigenetics. Synergy. Survival. 🧬💊📈 in in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.
A quiet but meaningful shift—targeting biology, not just burden.
#DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.
A quiet but meaningful shift—targeting biology, not just burden.
#DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
906 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
The Mel Robbins Podcast
20,222 Listeners